Literature DB >> 29750887

The effects of acute hypoxia on tissue oxygenation and circulating alarmins in healthy adults.

C J Boos1, C M Lamb, M Midwinter, A Mellor, D R Woods, M Howley, T Stansfield, M Foster, J P O'Hara.   

Abstract

The binding of high-mobility group box-1 (HMGB-1) to the membrane receptor for advanced glycation end-products (mRAGE) is a key early mediator of non-infectious inflammation and its triggers include ischaemia/hypoxia. The effects of acute hypoxia on soluble RAGE (sRAGE) are unknown. Fourteen healthy adults (50 % women; 26.6+/-3.8 years) were assessed at baseline normoxia (T0), followed by four time-points (T90, 95, 100 and 180 min) over three hours of continuous normobaric hypoxia (NH, 4,450 m equivalent) and again 60 min after return to normoxia (T240). A 5-min exercise step test was performed during NH at T90. Plasma concentrations of HMGB-1, sRAGE VCAM-1, ICAM-1, VEGF IL-8 and IL-13 were measured using venous blood. Arterial and tissue oxygen saturations were measured using pulse oximetry (SpO(2)) and near-infrared spectroscopy (StO(2)), respectively. NH led to a significant reduction in SpO(2), StO(2), sRAGE and VEGF, which was compounded by exercise, before increasing to baseline values with normoxic restoration (T240). NH-exercise led to a paired increase in HMGB-1. sRAGE inversely correlated with HMGB-1 (r=-0.32; p=0.006), heart rate (r=-0.43; p=0.004) but was not linked to SpO(2) or StO(2). In conclusion, short-term NH leads to a fall in sRAGE and VEGF concentrations with a transient rise post NH-exercise in HMGB-1.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29750887     DOI: 10.33549/physiolres.933743

Source DB:  PubMed          Journal:  Physiol Res        ISSN: 0862-8408            Impact factor:   1.881


  1 in total

1.  The effect of intermittent hypoxic exposure on erythropoietic response and hematological variables in elite athletes.

Authors:  A Kasperska; A Zembron-Lacny
Journal:  Physiol Res       Date:  2020-03-23       Impact factor: 1.881

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.